The agreement acquisition Production Unit of Sterilized Pharmaceuticals in Germany The Famar group announced by Mip Pharma.
According to the announcement, this acquisition is a strategic milestone in Famar’s development career, further enhancing its imprint on high value -added pharmaceutical dosage forms and expanding its productive potential in aseptic filling and packaging of products with lyophilization. The unit in Germany, which has recently been upgraded through significant investments that included significant modernization interventions, will be an integral part of Famar’s international production network.
Upon completion of the acquisition, Famar will now have 7 production facilities across Europe, enhancing its ability to serve its clientele with flexible, high quality and escalating production solutions.
“The Homburg unit has top infrastructure to produce sterile preparations, new, state -of -the -art quality control laboratories and microbiological laboratories, as well as specialized human resources,” he says. ” Constantine Regis, CEO of the Famar Group. “This investment is aligned with our strategy for the development and differentiation of the dosage forms we develop and enhance our ability to support an international clientele with services that meet the highest production standards. We are proud and very happy to welcome the Homburg team to the Famar family and look forward to building a strong, common future together. “
As part of the acquisition, about 100 unit workers will join the Famar human resources, ensuring its continuous operation and maintaining know -how. The unit will continue its operation now in the Famar network, with the aim of evolving it into a CDMO service platform for multiple customers, fully aligned with Famar’s ambition to be a leading force in the complex and high -value industry.
Ο Dr Friedrich Sernetz, CEO της MIP Pharmafor his part, the strategic importance of the agreement: “Thanks to the investments completed, the Homburg unit has evolved into an attractive asset for global pharmaceutical providers. In the Famar group we saw a partner who will not only maintain but further extend the unit’s dynamics. This agreement guarantees jobs and at the same time lays the foundations for further future growth. At the same time, it allows Mip Pharma to accelerate its own course, focusing on its main activity, the distribution of medicinal products. “
Matthew Strassberg, Partner and Head of Mideuropa Health Sector He said: “It makes us very happy that we support Famar in its mission to provide comprehensive and flexible solutions to its customers’ international portfolio. The acquisition of the Homburg unit is a tangible proof of Mideuropa’s commitment to support Famar in its fastest development, focusing on expanding the services provided and the production of high value -added pharmaceutical forms. “
Source: RES – EIA